Evidence map›Paper›PMID 41976405›Full record

ArticleCancers2026

Long-Term Young Adult Cancer Survivors with Ovarian Cancer: Subgroup Analysis of the Study "Expression VI-Carolin Meets HANNA-Holistic Analysis of Long-Term Survival with Ovarian Cancer": The International NOGGO, ENGOT, and GCIG Survey.

Desislava Dimitrova, Eleftherios Pierre Samartzis, Dario Zocholl, Maria-Pilar Barretina-Ginesta, Katharina Leitner, Pavel Havelka, Patriciu Achimas-Cadariu, Cagatay Taskiran, Suzana Mittelstadt, Els Van Nieuwenhuysen and 10 more

Abstract read
In one paragraph

Article in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Desislava DimitrovaDepartment of Gynecology with Center for Oncological Surgery, Charité-Universitätsmedizin Berlin, 13353 Berlin, Germany.ORCID 0000-0003-4228-5158
Eleftherios Pierre SamartzisDepartment of Gynecology, University Hospital of Zürich, 8091 Zürich, Switzerland.
Dario ZochollInstitute for Medical Biometry, Informatics and Epidemiology, University Hospital Bonn, University of Bonn, 53127 Bonn, Germany.
Maria-Pilar Barretina-GinestaMedical Oncology Department, Institut Català d'Oncologia, 17007 Girona, Spain.ORCID 0000-0003-0074-6614
Katharina LeitnerDepartment of Gynecology and Obstetrics, Medical University of Innsbruck, 6020 Innsbruck, Austria.ORCID 0000-0002-9572-9114
Pavel HavelkaTomas Bata Hospital Zlin, 760 01 Zlín, Czech Republic.ORCID 0009-0001-1857-549X
Patriciu Achimas-CadariuSurgical Oncology and Gynecologic Oncology, "Iuliu Hațieganu" University of Medicine and Pharmacy-Cluj-Napoca, 400012 Cluj-Napoca, Romania.ORCID 0000-0001-9928-5883
Cagatay TaskiranVKV American Hospital, 34365 Sisli, Turkey.
Suzana MittelstadtNorth-Eastern German Society for Gynecological Oncology (NOGGO), 13359 Berlin, Germany.ORCID 0000-0002-0833-0544
Els Van NieuwenhuysenUniversity Hospitals Leuven, 3000 Leuven, Belgium.ORCID 0000-0001-5432-1828
Gerd BauerschmitzNorth-Eastern German Society for Gynecological Oncology (NOGGO), 13359 Berlin, Germany.
Viola Heinzelmann-SchwarzSwiss GO Trial Group (Swiss GO), 4031 Basel, Switzerland.
Ainhoa MadariagaGrupo Español de Investigación en Cáncer de Ovario (GEICO), 28003 Madrid, Spain.ORCID 0000-0001-7166-9762
Uta RingsdorfNorth-Eastern German Society for Gynecological Oncology (NOGGO), 13359 Berlin, Germany.
Tibor ZwimpferSwiss GO Trial Group (Swiss GO), 4031 Basel, Switzerland.ORCID 0000-0002-1574-6572
Caterina MadroñalGrupo Español de Investigación en Cáncer de Ovario (GEICO), 28003 Madrid, Spain.
Hans-Martin EnzingerNorth-Eastern German Society for Gynecological Oncology (NOGGO), 13359 Berlin, Germany.
Sara Al RubaishDr. Sulaiman Al Habib Medical Group, Alkhober 34423, Saudi Arabia.ORCID 0000-0001-9117-090X
Jalid SehouliDepartment of Gynecology with Center for Oncological Surgery, Charité-Universitätsmedizin Berlin, 13353 Berlin, Germany.ORCID 0000-0002-5963-6623
Hannah WoopenDepartment of Gynecology with Center for Oncological Surgery, Charité-Universitätsmedizin Berlin, 13353 Berlin, Germany.ORCID 0000-0002-8617-5535

Funding

AstraZeneca GmbH NAGerman Ovarian Cancer Foundation NAJanssen-Cilag GmbH NAPfizer Pharma GmbH NARoche NATesaro NA
6 · The paper itself

Abstract

BACKGROUND/

objectivesOvarian cancer is typically diagnosed in postmenopausal women, so there are limited data available for young adult cancer survivors (YACS). The aim was to assess the patient perspective of YACS.

methodsIn this international and multicenter cross-sectional survey study, patient history, long-term side effects, and patient perspective were assessed. Long-term survival was defined as survival of at least five years after cancer diagnosis. Two groups were defined: (1) 18-40 years and (2) ≥41 years.

resultsAltogether, 1833 long-term survivors (LTS) have been recruited, with 1771 patients ≥41 years and 62 patients 18-40 years at recruitment. FIGO stages were similar; among the patients, 99.0% had received primary surgery followed by chemotherapy in 90.3%. Almost 50% still experienced long-term side effects. Patients ≤ 40 years reported more frequently not only gastrointestinal symptoms such as nausea/vomiting (44.4%,

conclusionsLong-term side effects are equally common in YACS after ovarian cancer, but with a focus on practical problems, mental health, gastrointestinal problems, and sexuality. This knowledge should be incorporated into follow-up care of ovarian cancer patients in order to improve quality of life.

Indexed as

cancer survivorshiplong-term side effectsovarian canceryoung adult cancer survivors

Identifiers

PMID41976405
PMCPMC13072019

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.